Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

NCT06600841 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

37

Enrollment

OTHER_GOV

Sponsor class

Conditions

Platinum-resistant Ovarian Cancer (PROC)
Immunotherapy

Interventions

DRUG: Immunotherapy（Adebrelimab）
DRUG: immunotherapy（Adebrelimab）

Sponsor

Fujian Cancer Hospital

Collaborators

[object Object]